Shilpa Medicare Limited Q3FY23 Earnings

With cutting-edge technology, Shilpa Medicare is in the business of manufacturing high-quality Active Pharmaceutical Ingredients, Intermediates, Formulations, Novel Drug delivery system, Peptides, Biotechnology goods, and Specialty chemicals. SML is among the top providers of oncology- and non-oncology-related intermediates and APIs in the world.

Financial Results – Management Commentary

“The company also undertook certain cost rationalization initiatives, which along with the improvement in our gross margin resulted in improving our EBITDA to INR34 crores, which is about 12.8% of our revenue from INR16.6 crores, which was 6.2% of our revenues during last quarter.

Now talking about the nine month performance. So our overall revenues stood at INR802 crores as compared to INR814 crores during corresponding period last year and gross profit stood at about INR475 crores, which was a margin of about 59%. Our EBITDA for the nine months stood at INR79 crores on a consolidated basis, that’s 9.9% on our top line.

And I would also like to quickly take you through our capex that we have incurred during the quarter at the Group level since ours is a manufacturing focused company. So in Q3, we have invested about INR53 crores in capex in various divisions, but predominantly, about INR43 crores have been invested in our Albumin facility and about INR10 crores have been invested in our — as maintenance capex in our API and formulations plants.“

– Alpesh Dalal, Chief Financial Officer (In Q3FY23 Concall)